Magnicor

Magnicor is an antithrombotic agent with combinatorial properties, the active components of which are acetylsalicylic acid and magnesium hydroxide.

[ 1 ]

Indications Magnicor

Indications for the use of the medical product Magnicor are as follows:

• Magnicor is recommended for use in acute ischemic heart disease, unstable angina, acute myocardial infarction.
• The use of the drug is indicated for chronic ischemic heart disease.
• This medicine is used for primary prevention of thrombosis.
• The drug is used to prevent the occurrence of blood clots after primary treatment.
• Magnicor is recommended for primary prevention of cardiovascular diseases, such as acute coronary syndrome in patients who are at risk of developing cardiovascular diseases due to provoking factors, namely:
• arterial hypertension,
• diabetes mellitus,
• obesity with a body mass index < 30,
• hypercholesterolemia,
• in patients under the age of fifty-five with a history of myocardial infarction.

Release form

Compound:

• active ingredients – each tablet contains 75 mg of acetylsalicylic acid and 15.2 mg of magnesium hydroxide;
• The excipients include a certain amount of corn starch, microcrystalline cellulose, potato starch, magnesium stearate, Opadry II White film coating mixture consisting of hydroxypropyl ethylcellulose, lactose monohydrate, polyethylene glycol, titanium dioxide (E 171), triacetin.

Form of release of the medicine:

• in round tablets, convex on both sides, covered with a film-like shell of white or close to white color;
• the tablets are packed in blisters of ten pieces;
• Each package contains three or ten blisters.

[ 2 ]

Pharmacodynamics

The pharmacodynamics of the drug Magnicor are as follows:

1. Acetylsalicylic acid, which is part of the drug, has anti-inflammatory, antipyretic, analgesic and antiplatelet effects. The basic result of this component of the drug is slowing down the production of prostaglandins and thromboxanes. The existing parallel result of pain relief is slowing down the processes of cyclooxygenase production. The anti-inflammatory effect is achieved by slowing down the synthesis of PGE2, due to which the blood flow rate decreases.
2. Due to the action of acetylsalicylic acid, the irreversible nature of prostaglandin synthesis of classes G/H is suppressed. This effect on these substances does not cease even when acetylsalicylic acid is completely eliminated from the body. This is a consequence of the effect of acetylsalicylic acid on the synthesis of thromboxanes, which are found in platelets. The clinical picture of this effect shows an increase in the bleeding period. Normalization of bleeding occurs over time, after the formation of new platelets.
3. Magnesium hydroxide, present in the medication, acts as an antacid component and as a protective substance for the epithelium of the stomach and intestines from the aggressive action of acetylsalicylic acid.

Pharmacokinetics

The pharmacokinetics of the drug Magnicor are as follows:

• After taking the medicine orally, the active components of the medicine immediately penetrate into the blood through the mucous membrane of the gastrointestinal tract. If you take Magnicor after meals, the rate of its absorption decreases. Reduced absorption of the active components of the medicine occurs in patients who are prone to migraines. Better absorption of the drug is observed in patients with achlorhydria or in patients who constantly use antacid medications and polysorbent drugs.
• The maximum content of active substances in the blood serum is observed about one and a half to two hours after taking Magnicor.
• Magnesium hydroxide is absorbed into the mucous membrane of the small intestine at a low rate and in small doses.
• The binding of acetylsalicylic acid to serum proteins is from 80 to 90 percent. The weight distribution share of the active components of Magnicor in adult patients is 170 ml per kg of body weight. Salicylates have the feature of rapid binding to proteins and rapid transportation to all organs and systems. Acetylsalicylic acid perfectly penetrates the placental and blood-brain barriers, appears in breast milk during lactation in significant quantities.
• Magnesium binds less well to serum proteins (approximately 25 to 30 percent). In this form, it is transported throughout the body and is able to penetrate the placental barrier. Some magnesium appears in breast milk during the lactation period.
• The transformation of acetylsalicylic acid in the epithelium of the stomach occurs to its most active component - salicylate. When absorbed through the mucous membranes, acetylsalicylic acid changes to salicylic acid at a high speed. Although in the first twenty minutes after taking Magnicor, the active component in unchanged form still prevails in the blood plasma.
• Salicylate changes to the final transformation products in the liver. The average half-life of the drug is two to three hours. If Magnicor was taken in a large dose, the half-life increases to 24-30 hours. Untransformed salicylates are excreted in the urine, and the level of urine acidity affects the amount of excretion of the substance. With an acid reaction, about two percent of salicylates are excreted, and with an alkaline reaction - up to thirty percent.
• Some magnesium is excreted from the body through urine, while the other part of the substance is reabsorbed and eliminated in the feces.
  

Dosing and administration

The method of administration and dosage of Magnilek are as follows:

1. Before starting to take Magnicor, it is imperative to consult with a specialist who will prescribe the duration of the course of treatment and the daily amount of medication based on the clinical picture of the disease.
2. The tablets are swallowed whole. Sometimes, for convenience, the tablet is divided into two parts, chewed or pre-crushed.
3. In acute or chronic ischemic heart disease, treatment should be started with a daily dose of 150 mg. The maintenance daily dose of the drug for these ailments is considered to be 75 mg.
4. In acute myocardial infarction, unstable angina, it is recommended to begin treatment with a daily dose of 150 - 450 mg. Use of the drug should be started immediately after the first symptoms of the disease are detected.
5. For the prevention of recurrent thrombosis, the initial daily dose of the drug is considered to be 150 mg; the maintenance daily dose is 75 mg.
6. For the initial prophylactic use in the case of blood clots, the daily dose of the drug is considered to be 150 mg.
7. For initial prevention of cardiovascular diseases (for example, acute coronary syndrome) in those patients who have predispositions for the development of cardiovascular diseases, the daily dose of the drug is 75 mg.

[ 4 ]

Use Magnicor during pregnancy

The use of Magnicor during pregnancy is possible only after consultation with a specialist.

If the positive result for the mother's body from the use of the drug exceeds the risk of threat to the development of the fetus, then the drug is prescribed for use in the first and second trimesters of pregnancy (from the first to the sixth month). At the same time, Magnicor is used only in the smallest quantities - up to 100 mg per one kg of body weight with constant monitoring by a specialist.

Magnicor should not be used during the third trimester of pregnancy.

Contraindications

Contraindications for the use of Magnicor are as follows: It should not be used in the following cases:

• Hypersensitivity to the components of the drug (salicylic acid and its derivatives).
• Gastric ulcer during the acute stage of the disease.
• There is a high risk of bleeding (with a lack of vitamin K, anemia, thrombocytopenia).
• Severe liver failure.
• Severe renal dysfunction (with a glomerular filtration rate of less than ten ml per minute).
• Obvious manifestations of heart failure.
• Asthma or Quincke's edema that occurs as a result of taking non-steroidal anti-inflammatory drugs or using salicylates in the treatment of diseases.
• Third trimester of pregnancy and lactation period.
• Age period up to 12 years.

Side effects Magnicor

Side effects of the drug Magnicor are divided into groups as follows:

1. Very common (more than one in ten cases).
2. Common (more than one in a hundred, less than one in ten).
3. Uncommon (more than one case in a thousand, less than one case in a hundred).
4. Rare (more than one case in ten thousand, less than one case in a thousand).
5. Very rare (less than one case in ten thousand), considering the isolated manifestations.

Side effects of the drug Magnicor:

Concerning the circulatory and lymphatic systems -

• very common - the appearance of severe bleeding, slowing down of platelet aggregation;
• uncommon – the appearance of latent bleeding;
• rarely common – the occurrence of anemia (with prolonged use of the drug);
• very rare - the appearance of hypothrombinemia (due to the use of large doses of the drug), thrombocytopenia, neutropenia, agranulocytosis, aplastic anemia, eosinophilia.

Concerning the central nervous system –

• common ones are the appearance of migraines, insomnia;
• uncommon – the appearance of dizziness (vertigo), drowsiness, sleep disorders, ringing in the ears;
• rarely common – occurrence of intracerebral hemorrhages, reversible changes in hearing acuity and deafness (with maximum amounts of drug use).

Related to the respiratory system -

• common – the appearance of bronchospasms (in asthmatic patients).

Concerning the digestive system –

• very common - the appearance of heartburn, reflux;

• common – the appearance of erosive lesions of the upper gastrointestinal tract, nausea, dyspepsia, vomiting, diarrhea;
• uncommon - the appearance of ulcers of the upper gastrointestinal tract, including vomiting of blood and tarry bowel movements;
• rarely common – the appearance of gastrointestinal bleeding, perforations;

• very rare - the appearance of stomatitis, esophagitis, toxic lesions with ulcers of the lower gastrointestinal tract, strictures, colitis, exacerbations of irritable bowel syndrome.

Liver related -

• rarely common – the level of transaminase and alkaline phosphatase in blood plasma increases;

• very rare - the occurrence of dose-dependent hepatitis of moderate severity in an acute form, which is reversible, the cause of which is an excess of the necessary doses of the drug several times.

Concerning skin and immunity –

• common – the appearance of urticaria, rashes of various types, angioedema, hemorrhagic vasculitis, purpura, erythema multiforme, Lyell's syndrome, Stevens-Johnson syndrome;
• uncommon – occurrence of anaphylactic reactions, allergic rhinitis.

Concerning the endocrine system –

• Rarely common - the occurrence of hypoglycemia.

[ 3 ]

Overdose

An overdose of the drug Magnilek manifests itself in the following:

1. A dangerous amount of medication, which may cause overdose symptoms, is a daily amount of medication for adults greater than 150 mg per kg of the patient's body weight.
2. Due to long-term use of large quantities of the drug (over 150 mg per day), signs of chronic moderate poisoning may appear. Sometimes dizziness and headaches, confusion, deafness, tinnitus, dilation of blood vessels, sweating, nausea, and vomiting may occur.
3. Severe poisoning with the drug provokes the following symptoms: sudden anxiety, excessive pulmonary ventilation, alkaloid alkalosis, severe increase in body temperature, ketosis, metabolic acidosis. In case of severe poisoning with the drug, the central nervous system is suppressed, which can provoke a state of coma, cardiovascular collapse and respiratory arrest.
4. In acute salicylate poisoning, symptoms of acute liver failure often occur (with a daily dose of the drug exceeding 300 mg per kg of body weight).
5. A lethal dose of the drug is more than 500 mg per kg of body weight.
6. Treatment of overdose: In case of acute overdose, it is necessary to immediately wash out the stomach and then use activated carbon. It is necessary to restore the water-electrolyte balance to prevent the occurrence of acidosis, critical loss of fluid in the body, hyperpyrexia and hyperkalemia. Sometimes it is necessary to use the following effective methods of absorbing toxins from the blood serum - hemodialysis, hemoperfusion and alkaline diuresis.

Interactions with other drugs

The interaction of Magnicor with other drugs is as follows:

1. When used in parallel, Magnicor increases the effectiveness of anticoagulants - warfarin, heparin, clopidogrel, phenprocoumon and hypoglycemic drugs.
2. Magnicor has the ability to suppress the diuretic effect of furosemide, as well as spinolactone, ATP inhibitors.
3. Do not use Magnicor together with nonsteroidal anti-inflammatory drugs. Antacid drugs reduce the absorption of the above medications.
4. The use of Magnicor in parallel with probenecid reduces the effect of both medications.
5. No strong interactions have been reported between the parallel use of acetylsalicylic acid and magnesium due to the low magnesium content of Magnicor.

[ 5 ], [ 6 ]

Storage conditions

Storage conditions for Magnicor are as follows:

• In the packaging in which the medicine was released.
• At normal temperatures no more than twenty-five degrees.
• In childproof storage.
  

Shelf life

The shelf life of the drug Magnicor, if the conditions of proper storage are met, is two years from the date of manufacture.